<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615508</url>
  </required_header>
  <id_info>
    <org_study_id>COMIRB 18-0620</org_study_id>
    <nct_id>NCT03615508</nct_id>
  </id_info>
  <brief_title>Exploration of Pupil Dilation in Horner's Patients Taking Flomax</brief_title>
  <official_title>Exploration of Pupil Dilation in Horner's Patients Taking Flomax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denver Health and Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Denver Health and Hospital Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the pupil dilation of Horner's Patients who have ever taken an alpha
      blocker such as Tamsulosin. Patients will undergo eye dilation as would occur at a yearly eye
      examination, but their pupil dilation measurements will be recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll 10 participants who have a unilateral Horner's Syndrome AND have a
      history of taking an alpha blocker such as Tamsulosin. Participants will be recruited based
      on those two enrollment criteria, and after consenting they will undergo pupil dilation with
      10% phenylephrine. Once fully dilated the pupil size will be measured. Pupil dilation size of
      the eye affected by the Horner's Syndrome will be compared to the eye not affected by
      Horner's. Primary study outcome is the comparative dilation size of the Horner's affected eye
      to the non affected eye in all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, intervention trial.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pupil Size Measurements</measure>
    <time_frame>20-30 minutes after 10% phenylephrine has been placed in each eye.</time_frame>
    <description>pupil dilation measurements will be taken of each eye at the eye examination.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Horner Syndrome</condition>
  <arm_group>
    <arm_group_label>10% phenylephrine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% phenylephrine</intervention_name>
    <description>10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.</description>
    <arm_group_label>10% phenylephrine</arm_group_label>
    <other_name>Phenylephrine 10%, Pupil Dilation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Horner's Syndrome

          2. History of taking an alpha blocker (tamsulosin/
             terazosin/doxazosin/alfuzosin/silodosin) medication

        Exclusion Criteria:

          1. Subjects with untreated hypertension

          2. Subjects with thyrotoxicosis

          3. Pregnant women

          4. Prisoners

          5. Inability to consent

          6. Subjects with anatomical narrow angles who have never had a dilated exam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristos Ifantides, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristos Ifantides, MD</last_name>
    <phone>352-514-1422</phone>
    <email>cristos.ifantides@dhha.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexis Cralley, MD</last_name>
    <phone>303-602-5423</phone>
    <email>alexis.cralley@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Hospital, Rocky Mountain Lions Eye Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristos Ifantides, MD</last_name>
      <phone>352-514-1422</phone>
      <email>cristos.ifantides@dhha.org</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Cralley, MD</last_name>
      <phone>303-602-5423</phone>
      <email>alexis.cralley@dhha.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Denver Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristos Ifantides, MD</last_name>
      <phone>352-514-1422</phone>
      <email>cristos.ifantides@dhha.org</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Cralley, MD</last_name>
      <phone>303-602-5423</phone>
      <email>alexis.cralley@dhha.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Denver Health and Hospital Authority</investigator_affiliation>
    <investigator_full_name>Cristos Ifantides, MD, MBA</investigator_full_name>
    <investigator_title>Associate Professor, Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Alpha blockers</keyword>
  <keyword>Tamsulosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Horner Syndrome</mesh_term>
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

